{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:37:55Z","timestamp":1788950275177,"version":"build-2803163510"},"reference-count":34,"publisher":"FapUNIFESP (SciELO)","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. bras. pneumol."],"abstract":"<jats:p>ABSTRACT  Objectives: To characterize the main identified mutations on cystic fibrosis transmembrane conductance regulator (CFTR) in a group of children and adolescents at a cystic fibrosis center and its association with the clinical and laboratorial characteristics.  Method:  Descriptive cross-sectional study including patients with cystic fibrosis who had two alleles identified with CFTR mutation. Clinical, anthropometrical, laboratorial and pulmonary function (spirometry) data were collected from patients\u2019 records in charts and described with the results of the sample genotyping.  Results:  42 patients with cystic fibrosis were included in the study. The most frequent mutation was F508del, covering 60 alleles (71.4%). The second most common mutation was G542X (six alleles, 7.1%), followed by N1303K and R1162X mutations (both with four alleles each). Three patients (7.14%) presented type III and IV mutations, and 22 patients (52.38%) presented homozygous mutation for F508del. Thirty three patients (78.6%) suffered of pancreatic insufficiency, 26.2% presented meconium ileus, and 16.7%, nutritional deficit. Of the patients in the study, 59.52% would be potential candidates for the use of CFTR-modulating drugs.  Conclusions: The mutations of CFTR identified more frequently were F508del and G542X. These are type II and I mutations, respectively. Along with type III, they present a more severe cystic fibrosis phenotype. More than half of the sample (52.38%) presented homozygous mutation for F508del, that is, patients who could be treated with Lumacaftor\/Ivacaftor. Approximately 7% of the patients (7.14%) presented type III and IV mutations, therefore becoming candidates for the treatment with Ivacaftor.<\/jats:p>","DOI":"10.1590\/s1806-37562017000000418","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T19:56:34Z","timestamp":1549396594000},"page":"498-504","source":"Crossref","is-referenced-by-count":5,"title":["Genetic and phenotypic traits of children and adolescents with cystic fibrosis in Southern Brazil"],"prefix":"10.1590","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7120-3022","authenticated-orcid":false,"given":"Katiana Murieli da","family":"Rosa","sequence":"first","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2350-9443","authenticated-orcid":false,"given":"Eliandra da Silveira de","family":"Lima","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5138-3046","authenticated-orcid":false,"given":"Camila Correia","family":"Machado","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4421-8995","authenticated-orcid":false,"given":"Thaiane","family":"Rispoli","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3264-0374","authenticated-orcid":false,"given":"Vict\u00f3ria d\u2019Azevedo","family":"Silveira","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0217-3792","authenticated-orcid":false,"given":"Renata","family":"Ongaratto","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3574-6318","authenticated-orcid":false,"given":"Talitha","family":"Comaru","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3906-5456","authenticated-orcid":false,"given":"Leonardo Ara\u00fajo","family":"Pinto","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2018,12]]},"reference":[{"issue":"10059","key":"ref1","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn JS","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2015.10.002","article-title":"Epidemiology of Cystic Fibrosis","volume":"37","author":"Spoonhower KA","year":"2016","journal-title":"Clin Chest Med"},{"key":"ref3","series-title":"Portal"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccm.2015.11.002","article-title":"Genetics of Cystic Fibrosis Clinical Implications","volume":"37","author":"Egan ME","year":"2016","journal-title":"Clin Chest Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.biocel.2014.02.008","article-title":"Cystic fibrosis toward personalized therapies","volume":"52","author":"Ikpa PT","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/thoraxjnl-2015-208123","article-title":"Advancing clinical development pathways for new CFTR modulators in cystic fibrosis","volume":"71","author":"Mayer-Hamblett N","year":"2016","journal-title":"Thorax"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.pcl.2016.04.002","article-title":"Molecular Genetics of Cystic Fibrosis Transmembrane Conductance Regulator Genotype and Phenotype","volume":"63","author":"Sosnay PR","year":"2016","journal-title":"Pediatr Clin North Am"},{"issue":"1","key":"ref8","first-page":"3","article-title":"Cystic Fibrosis A Review of Associated Phenotypes, Use of Molecular Diagnostic Approaches, Genetic Characteristics, Progress, and Dilemmas","volume":"18","author":"Brennan ML","year":"2016","journal-title":"J Mol Diagn"},{"key":"ref9","series-title":"Portal"},{"key":"ref10","series-title":"Portal"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1590\/S0100-879X2005000100003","article-title":"Prevalence of deltaF508, G551D, G542X, and R553X mutations among cystic fibrosis patients in the North of Brazil","volume":"38","author":"Ara\u00fajo FG","year":"2005","journal-title":"Braz J Med Biol Res"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1590\/S1806-37132013000500005","article-title":"Cystic fibrosis transmembrane conductance regulator mutations at a referral center for cystic fibrosis","volume":"39","author":"Coutinho CA","year":"2013","journal-title":"J Bras Pneumol"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/gim.2015.79","article-title":"Prevalence of meconium ileus marks the severity of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene","volume":"18","author":"Dupuis A","year":"2016","journal-title":"Genet Med"},{"issue":"18","key":"ref14","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1056\/NEJM199310283291804","article-title":"Correlation between genotype and phenotype in patients with cystic fibrosis","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/BF00221957","article-title":"Incidence and expression of the N1303K mutation of the cystic fibrosis (CFTR) gene","volume":"89","author":"Osborne L","year":"1992","journal-title":"Hum Genet"},{"key":"ref16","series-title":"Fibrose C\u00edstica: Estudo das Varia\u00e7\u00f5es de Sequ\u00eancia do Gene CFTR na Popula\u00e7\u00e3o Pedi\u00e1trica Portuguesa","author":"Gon\u00e7alves LCS","year":"2013"},{"issue":"2","key":"ref17","first-page":"160","article-title":"A Gen\u00e9tica na Fibrose C\u00edstica","volume":"31","author":"Saraiva-Pereira ML","year":"2011","journal-title":"Rev HCPA"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"138103","DOI":"10.1155\/2015\/138103","article-title":"N1303K (c 3909C&gt;G) Mutation and Splicing: Implication of Its c.[744-33GATT(6); 869+11C&gt;T] Complex Allele in CFTR Exon 7 Aberrant Splicing","volume":"2015","author":"Farhat R","year":"2015","journal-title":"Biomed Res Int"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1017\/S0003480097006477","article-title":"Genetic history of cystic fibrosis mutations in Italy I. Regional distribution","volume":"61","author":"Rendine S","year":"1997","journal-title":"Ann Hum Genet"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcf.2008.03.009","article-title":"Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice","volume":"7","author":"Castellani C","year":"2008","journal-title":"J Cyst Fibros"},{"issue":"12","key":"ref21","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/jmg.28.12.875","article-title":"A cystic fibrosis patient who is homozygous for the G85E mutation has very mild disease","volume":"28","author":"Chalkley G","year":"1991","journal-title":"J Med Genet"},{"key":"ref22","series-title":"A Quick Guide to the G85E Mutation","year":"2016"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/hmg\/2.10.1741","article-title":"Identification of a new missense mutation (P205S) in the first transmembrane domain of the CFTR gene associated with a mild cystic fibrosis phenotype","volume":"2","author":"Chill\u00f3n M","year":"1993","journal-title":"Hum Mol Genet"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/jmg.38.11.777","article-title":"Cystic fibrosis patients with the 3272-26A&gt;G splicing mutation have milder disease than F508del homozygotes a large European study","volume":"38","author":"Amaral MD","year":"2001","journal-title":"J Med Genet"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/jmg.32.5.406","article-title":"Mild cystic fibrosis phenotype in patients with the 3272-26A &gt; G mutation","volume":"32","author":"Kanavakis E","year":"1995","journal-title":"J Med Genet"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/jmg.35.1.84-a","article-title":"Cystic fibrosis in a Puerto Rican female homozygous for the R1066C mutation","volume":"35","author":"Liang MH","year":"1998","journal-title":"J Med Genet"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1399-0004.2009.01294.x","article-title":"Non-classic cystic fibrosis associated with D1152H CFTR mutation","volume":"77","author":"Burgel PR","year":"2010","journal-title":"Clin Genet"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jcf.2004.07.004","article-title":"Genotype-phenotype relationship for five CFTR mutations frequently identified in western France","volume":"3","author":"Dugu\u00e9p\u00e9roux I","year":"2004","journal-title":"J Cyst Fibros"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/jmg.31.2.159","article-title":"Association of 1078 del T cystic fibrosis mutation with severe disease","volume":"31","author":"Moullier P","year":"1994","journal-title":"J Med Genet"},{"issue":"3","key":"ref30","first-page":"CD009841","article-title":"Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis","volume":"26","author":"Patel S","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"ref31","series-title":"Cystic fibrosis: Investigational therapies","author":"Simon RH","year":"2017"},{"issue":"3","key":"ref32","first-page":"219","article-title":"Diretrizes brasileiras de diagn\u00f3stico e tratamento da fibrose c\u00edstica","volume":"43","author":"Athanazio RA","year":"2017","journal-title":"J Bras Pneumol"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright CE","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"ref34","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation a phase 2 randomised controlled trial","volume":"2","author":"Boyle MP","year":"2014","journal-title":"Lancet Respir Med"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/jbpneu\/v44n6\/1806-3713-jbpneu-44-06-00498.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T17:28:15Z","timestamp":1579886895000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1806-37132018000600498&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["S1806-37132018000600498"],"URL":"https:\/\/doi.org\/10.1590\/s1806-37562017000000418","relation":{},"ISSN":["1806-3756","1806-3713"],"issn-type":[{"value":"1806-3756","type":"electronic"},{"value":"1806-3713","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}